JP2001524928A - クロスプライミング免疫による天然抗原に特異性を有するctlの誘導 - Google Patents
クロスプライミング免疫による天然抗原に特異性を有するctlの誘導Info
- Publication number
- JP2001524928A JP2001524928A JP50415598A JP50415598A JP2001524928A JP 2001524928 A JP2001524928 A JP 2001524928A JP 50415598 A JP50415598 A JP 50415598A JP 50415598 A JP50415598 A JP 50415598A JP 2001524928 A JP2001524928 A JP 2001524928A
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- artificial target
- antigen
- cells
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108091007433 antigens Proteins 0.000 title claims abstract description 173
- 102000036639 antigens Human genes 0.000 title claims abstract description 173
- 239000000427 antigen Substances 0.000 title claims abstract description 170
- 230000036039 immunity Effects 0.000 title claims description 35
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 title abstract description 12
- 230000006698 induction Effects 0.000 title description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 124
- 230000003053 immunization Effects 0.000 claims abstract description 103
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 68
- 210000000448 cultured tumor cell Anatomy 0.000 claims abstract description 26
- 238000000338 in vitro Methods 0.000 claims abstract description 23
- 238000002649 immunization Methods 0.000 claims description 101
- 210000004027 cell Anatomy 0.000 claims description 86
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 230000001404 mediated effect Effects 0.000 claims description 21
- 230000004044 response Effects 0.000 claims description 17
- 102000011931 Nucleoproteins Human genes 0.000 claims description 15
- 108010061100 Nucleoproteins Proteins 0.000 claims description 15
- 230000000259 anti-tumor effect Effects 0.000 claims description 13
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 claims description 12
- 238000001890 transfection Methods 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- 241000712461 unidentified influenza virus Species 0.000 claims description 10
- 230000002163 immunogen Effects 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 6
- 101800001271 Surface protein Proteins 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 241000287828 Gallus gallus Species 0.000 claims description 4
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 102000016200 MART-1 Antigen Human genes 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 39
- 108091054437 MHC class I family Proteins 0.000 abstract description 23
- 102000043129 MHC class I family Human genes 0.000 abstract description 21
- 230000028993 immune response Effects 0.000 abstract description 19
- 230000005809 anti-tumor immunity Effects 0.000 abstract description 3
- 230000007236 host immunity Effects 0.000 abstract description 2
- 108010058846 Ovalbumin Proteins 0.000 description 73
- 229940092253 ovalbumin Drugs 0.000 description 66
- 241000699670 Mus sp. Species 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 34
- 210000004443 dendritic cell Anatomy 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 201000001441 melanoma Diseases 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 22
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 22
- 239000011324 bead Substances 0.000 description 19
- 210000000612 antigen-presenting cell Anatomy 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 230000037361 pathway Effects 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000012634 fragment Substances 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 9
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 208000036142 Viral infection Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 208000001382 Experimental Melanoma Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 4
- 210000000172 cytosol Anatomy 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000008732 thymoma Diseases 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 210000000991 chicken egg Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 108060003552 hemocyanin Proteins 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000004726 long-term protective immunity Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101100207408 Homo sapiens TRA gene Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000680 phagosome Anatomy 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- WLWIMKWZMGJRBS-UHFFFAOYSA-N primin Chemical compound CCCCCC1=CC(=O)C=C(OC)C1=O WLWIMKWZMGJRBS-UHFFFAOYSA-N 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000037455 tumor specific immune response Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241001522296 Erithacus rubecula Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101710121925 Hemagglutinin glycoprotein Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 101000924587 Mus musculus Adenomatous polyposis coli protein Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳類宿主における抗腫瘍免疫の方法であって、 a)CTL媒介応答を促進する形態で、人工標的抗原を用いて、哺乳類の宿主に 第1の免疫を施し、 b)哺乳類の宿主から標的腫瘍を切除し、 c)標的細胞から回収した腫瘍細胞の群をインビトロで培養し、 d)培養された腫瘍細胞が、細胞表面における人工標的抗原の存在を促進する ようにするため、該培養腫瘍細胞を、該腫瘍細胞内に人工標的抗原が含まれるよ うに処理し、 e)培養腫瘍細胞群を不活化し、 f)不活化された培養腫瘍細胞群を用いて、哺乳類の宿主に第2の免疫を施す 、 工程を有している哺乳類宿主の抗腫瘍免疫方法。 2.哺乳類はヒトである請求項1の方法。 3.工程(a)の人工標的抗原は、哺乳類の宿主に対し、粒子状複合物として提供 される請求項2の方法。 4.工程(d)の人工標的抗原は、有効量の人工標的抗原を発現する核酸分子のト ランスフェクションにより、培養腫瘍細胞へ導入される請求項2の方法。 5.工程(d)の人工標的抗原は、有効量の人工標的抗原を発現する核酸分子のト ランスフェクションにより、培 養腫瘍細胞へ導入される請求項3の方法。 6.工程(d)の人工標的抗原は、ペプチドパルシングにより、培養腫瘍細胞へ導 入される請求項2の方法。 7.工程(d)の人工標的抗原は、ペプチドパルシングにより、培養腫瘍細胞へ導 入される請求項3の方法。 8.人工標的抗原は、Melan−A、p53、CEA、gp100、MAGE−1及びMAGE−2からな る群から選択される腫瘍抗原である請求項3、4、5、6又は7の方法。 9.人工標的抗原は、HIV gp 120、HIV gp100、インフルエンザウイルス核蛋白 質及びB型肝炎表面抗原からなる群から選択されるウイルス抗原である請求項3 、4、5、6又は7の方法。 10.人工標的抗原は、ニワトリオバルブミン及びキーホールリンピットヘモシ アニンからなる群から選択される免疫原性外部抗原である請求項3、4、5、6 又は7の方法。 11.人工標的抗原はニワトリのオバルブミンである請求項3、4、5、6又は 7の方法。 12.哺乳類宿主における抗腫瘍免疫の方法であって、 a)哺乳類の宿主から標的腫瘍を切除し、 b)標的細胞から回収した腫瘍細胞の群をインビトロで培養し、 c)培養された腫瘍細胞が、細胞表面における人工標的抗原の存在を促進する ようにするため、該培養腫瘍 細胞を、該腫瘍細胞内に人工標的抗原が含まれるように処理し、 d)培養腫瘍細胞群を不活化し、 e)哺乳類の宿主に対し、不活化された培養腫瘍細胞群による第1の免疫と、 CTL媒介応答を促進する形態にて、人工標的抗原による第2の免疫を同時に行な う、 工程を有している哺乳類宿主の抗腫瘍免疫方法。 13.哺乳類はヒトである請求項12の方法。 14.工程(a)の人工標的抗原は、哺乳類の宿主に対し、粒子状複合物として提 供される請求項13の方法。 15.工程(d)の人工標的抗原は、有効量の人工標的抗原を発現する核酸分子の トランスフェクションにより、培養腫瘍細胞へ導入される請求項13の方法。 16.工程(d)の人工標的抗原は、有効量の人工標的抗原を発現する核酸分子の トランスフェクションにより、培養腫瘍細胞へ導入される請求項14の方法。 17.工程(d)の人工標的抗原は、ペプチドパルシングにより、培養腫瘍細胞へ 導入される請求項13の方法。 18.工程(d)の人工標的抗原は、ペプチドパルシングにより、培養腫瘍細胞へ 導入される請求項14の方法。 19.人工標的抗原は、Melan−A、p53、CEA、gp100、MAGE−1及びMAGE−2から なる群から選択される腫瘍抗原である請求項14、15、16、17又は18の 方法。 20.人工標的抗原は、HIV gp120、HIV gp100、インフ ルエンザウイルス核蛋白質及びB型肝炎表面抗原からなる群から選択されるウイ ルス抗原である請求項14、15、16、17又は18の方法。 21.人工標的抗原は、ニワトリオバルブミン及びキーホールリンピットヘモシ アニンからなる群から選択される免疫原性外部抗原である請求項14、15、1 6、17又は18の方法。 22.人工標的抗原はニワトリのオバルブミンである請求項14、15、16、 17又は18の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/675,332 US5951975A (en) | 1996-06-28 | 1996-06-28 | Induction of CTLs specific for natural antigens by cross priming immunization |
US08/675,332 | 1996-06-28 | ||
PCT/US1997/010195 WO1998000163A1 (en) | 1996-06-28 | 1997-06-18 | INDUCTION OF CTLs SPECIFIC FOR NATURAL ANTIGENS BY CROSS-PRIMING IMMUNIZATION |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001524928A true JP2001524928A (ja) | 2001-12-04 |
JP2001524928A5 JP2001524928A5 (ja) | 2005-03-10 |
Family
ID=24710012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50415598A Ceased JP2001524928A (ja) | 1996-06-28 | 1997-06-18 | クロスプライミング免疫による天然抗原に特異性を有するctlの誘導 |
Country Status (7)
Country | Link |
---|---|
US (1) | US5951975A (ja) |
EP (1) | EP1007087A1 (ja) |
JP (1) | JP2001524928A (ja) |
AU (1) | AU724546B2 (ja) |
CA (1) | CA2258840A1 (ja) |
IL (1) | IL127661A (ja) |
WO (1) | WO1998000163A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021029424A1 (ja) * | 2019-08-13 | 2021-02-18 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 免疫記憶に基づく新規疾患治療および予防 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US6994851B1 (en) * | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
JP2002510647A (ja) * | 1998-04-08 | 2002-04-09 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 癌の治療のための方法および修飾細胞 |
US6844188B1 (en) | 1998-04-08 | 2005-01-18 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
CA2358915C (en) | 1998-12-31 | 2010-06-01 | Chiron Corporation | Modified hiv env polypeptides |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
CA2358385C (en) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
CA2360347C (en) | 1998-12-31 | 2013-05-07 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
US8128922B2 (en) * | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
JP5087201B2 (ja) * | 2000-08-03 | 2012-12-05 | ジョンズ・ホプキンス・ユニバーシティ | 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン |
GB0026812D0 (en) * | 2000-11-02 | 2000-12-20 | Isis Innovation | Cancer therapy |
CA2489019A1 (en) * | 2001-06-15 | 2002-12-27 | Nordic Vaccine Technology A/S | Therapeutical vaccination |
JP5033303B2 (ja) * | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用 |
US20030198621A1 (en) * | 2001-07-05 | 2003-10-23 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
CA2458995C (en) * | 2001-08-31 | 2013-04-30 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
DK1620456T3 (da) * | 2003-04-18 | 2014-04-22 | Biotech Synergy Inc | Hla-a2 tumor-associerede antigen-peptider og præparater |
WO2004098526A2 (en) * | 2003-05-05 | 2004-11-18 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
WO2004100984A1 (en) * | 2003-05-13 | 2004-11-25 | The University Of Massachusetts | Endogenous adjuvant molecules and uses thereof |
WO2006085983A2 (en) * | 2004-07-09 | 2006-08-17 | University Of North Carolina At Chapel Hill | Viral adjuvants |
AU2005322960A1 (en) * | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines |
WO2006081323A2 (en) * | 2005-01-26 | 2006-08-03 | The Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin |
CA2597921A1 (en) * | 2005-02-15 | 2007-04-26 | University Of North Carolina At Chapel Hill | New live virus vaccines |
WO2008024844A2 (en) * | 2006-08-22 | 2008-02-28 | The Johns Hopkins University | Anticancer combination therapies |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
US20080260765A1 (en) * | 2007-03-15 | 2008-10-23 | Johns Hopkins University | HPV DNA Vaccines and Methods of Use Thereof |
US20090285861A1 (en) * | 2008-04-17 | 2009-11-19 | Tzyy-Choou Wu | Tumor cell-based cancer immunotherapeutic compositions and methods |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3630126A4 (en) * | 2017-06-02 | 2021-03-17 | The Penn State Research Foundation | CERAMIDE NANOLIPOSOMES, COMPOSITIONS AND METHODS OF USE FOR IMMUNOTHERAPY |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5045320A (en) * | 1989-03-23 | 1991-09-03 | Medical Biology Institute | Large multivalent immunogen |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
WO1995024217A1 (en) * | 1994-03-08 | 1995-09-14 | Dana-Farber Cancer Institute | Methods for modulating t cell unresponsiveness |
-
1996
- 1996-06-28 US US08/675,332 patent/US5951975A/en not_active Expired - Fee Related
-
1997
- 1997-06-18 AU AU33900/97A patent/AU724546B2/en not_active Ceased
- 1997-06-18 CA CA002258840A patent/CA2258840A1/en not_active Abandoned
- 1997-06-18 EP EP97929960A patent/EP1007087A1/en not_active Withdrawn
- 1997-06-18 WO PCT/US1997/010195 patent/WO1998000163A1/en not_active Application Discontinuation
- 1997-06-18 JP JP50415598A patent/JP2001524928A/ja not_active Ceased
- 1997-06-18 IL IL12766197A patent/IL127661A/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021029424A1 (ja) * | 2019-08-13 | 2021-02-18 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 免疫記憶に基づく新規疾患治療および予防 |
Also Published As
Publication number | Publication date |
---|---|
IL127661A (en) | 2001-11-25 |
CA2258840A1 (en) | 1998-01-08 |
EP1007087A1 (en) | 2000-06-14 |
AU724546B2 (en) | 2000-09-28 |
AU3390097A (en) | 1998-01-21 |
WO1998000163A1 (en) | 1998-01-08 |
US5951975A (en) | 1999-09-14 |
IL127661A0 (en) | 1999-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001524928A (ja) | クロスプライミング免疫による天然抗原に特異性を有するctlの誘導 | |
Chen et al. | Experimental vaccine strategies for cancer immunotherapy | |
Tiptiri-Kourpeti et al. | DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy | |
WO1998000163A9 (en) | INDUCTION OF CTLs SPECIFIC FOR NATURAL ANTIGENS BY CROSS-PRIMING IMMUNIZATION | |
JP2019531090A (ja) | 改変されたvsv−gおよびそのワクチン | |
Niethammer et al. | An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice | |
CA2717854C (en) | Allogeneic cancer cell-based immunotherapy | |
US20020187131A1 (en) | Enhanced antigen delivery and modulation of the immune response therefrom | |
JP2003523398A (ja) | 樹状細胞のインビボ活性化によるアジュバント治療 | |
JP2003532686A (ja) | 抗原−抗体複合体化および樹状細胞による提示を利用する治療法および組成物 | |
IL173943A (en) | Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris) | |
JP7384896B2 (ja) | 主要組織適合遺伝子複合(mhc)クラスii-発現癌細胞ワクチン、及び統合免疫応答を生じさせるための使用方法 | |
Fang et al. | The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model | |
Vangasseri et al. | Lipid-protamine-DNA-mediated antigen delivery | |
JP2023507347A (ja) | ネオエピトープをコードするコンストラクトを使用する核酸ワクチン接種 | |
AU716497B2 (en) | Stimulation of cell-mediated immune responses by targeted particulate genetic immunization | |
WO1999030734A1 (en) | Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity | |
US7176186B1 (en) | Stimulation of cell-mediated immune responses by targeted particulate genetic immunization | |
Nawrath et al. | Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model | |
JP2001501220A (ja) | オンコジーン産物および外来mhc分子を用いる癌治療 | |
Gadhave et al. | DNA vaccines: A hope full ray in Immunology | |
Jang et al. | Simultaneous expression of allogenic class II MHC and B7. 1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity | |
JP4459060B2 (ja) | ポリヌクレオチドからなるワクチン | |
Stevenson et al. | DNA vaccination against cancer antigens | |
JP2003527322A (ja) | 細胞内病原体に対するワクチン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040616 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040616 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080411 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080526 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080902 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081111 |